Telix Illuccix
Radiopharmaceuticals
Telix Pharmaceuticals
Global theranostics leader advancing targeted radiopharmaceuticals across imaging, therapy and integrated precision oncology platforms.
Telix is a commercial-stage biopharmaceutical company specialising in diagnostic and therapeutic radiopharmaceuticals for precision oncology. Its portfolio spans prostate, kidney, brain and rare cancers, with multiple late-stage therapeutic programmes including TLX591, TLX250 and TLX101.
Illuccix® is approved in the UK for prostate cancer imaging, reflecting strong regulatory and commercial traction.
Telix operates a vertically integrated manufacturing network across Europe, North America and Asia, strengthened by its U.S. radiopharmacy network acquisition.
Through proprietary cyclotron technology and integrated MedTech tools, Telix connects imaging, therapy and surgical support to deliver end-to-end, patient-specific cancer care.
Sort by
